Back to Home > Business > Press Releases > Press Releases - Medical

Press Releases - Medical   RSS Add to My Yahoo

Top Story

  • New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR

    Many strong acting pain medications have bothersome side effects. These can include nausea and vomiting with short-term use, and constipation with longer, chronic use. Such symptoms can lead patients to discontinue treatment, adding additional complications to pain management for physicians. The novel investigational medication tapentadol, a centrally acting oral analgesic, provided pain relief for patients with fewer gastrointestinal side effects than those treated with an older, prescription pain reliever, researchers announced today.

MORE STORIES

  • Noven to Present at R.W. Baird Growth Stock Conference

    Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced that Jeffrey F. Eisenberg, Noven's Executive Vice President, is scheduled to present an update on Noven's business and prospects at the Robert W. Baird 2008 Growth Stock Conference in Chicago, IL on Tuesday, May 13 at 1:55 p.m. CT (2:55 p.m. ET). The presentation will be webcast live at www.noven.com, and a rebroadcast will be available thereafter at the same site.

  • Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile

    Osteoarthritis is a painful and potentially debilitating condition that affects almost 50 million people in the United States. It is caused by deterioration of cartilage in bone joints. The novel investigational pain medication tapentadol, a centrally acting oral analgesic, provided significant relief for patients with joint-disease pain, compared to those treated with placebo, and with fewer gastrointestinal side effects than those treated with an older, prescription pain reliever, researchers announced today.

  • New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery

    Many foot-surgery patients experience intense pain for several days following removal of a bunion, one of the most common foot surgeries. The investigational pain medication tapentadol provided significant relief for patients who had this surgery, compared to those treated with placebo. Treatment with tapentadol also resulted in patients reporting fewer gastrointestinal side effects compared to those treated with an older, prescription pain reliever, researchers announced today.

  • Moffitt Cancer Center Joins National Campaign To Implore Americans To Donate $1 To Accelerate Cancer Research

    The Cancer Research Alliance, an organization comprised of 12 of the nation's best cancer centers including Moffitt Cancer Center, is asking all 303 million Americans to exercise their power over cancer by stepping up and donating $1 to cancer research efforts this Mother's Day through Father's Day.

  • University Health Industries Announces New Name and Ticker Symbol

    University Health Industries, Inc., (OTC:UVHI) a Florida corporation engaged in the development, marketing and sale of proprietary, patent-pending nutraceutical products, including its leading brands Arthroleve(TM) and Zenstral PMS(TM), announces new name and ticker symbol.

  • AACE Calls for New Standards for Safer Insulin Pump Use

    "The American Association of Clinical Endocrinologists applauds the FDA's efforts to protect the safety of children and adolescents who are using insulin pumps," said Dr. Richard Hellman, the Association's President.

  • Exactech Announces Sale of Common Stock Resulting in $20.2 Million in Gross Proceeds

    Exactech Inc. (Nasdaq:EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that it has entered into definitive agreements with certain institutional investors to sell 877,391 shares of its common stock at a price of $23.00 per share, resulting in gross proceeds of approximately $20.2 million and net proceeds of approximately $18.8 million after offering expenses and placement agency fees. Exactech offered the shares pursuant to an effective registration statement previously filed with the Securities and Exchange Commission. The offering is expected to close on or before May 14, 2008 and is subject to certain closing conditions.

  • PainCare to Voluntarily Delist from American Stock Exchange

    PainCare Holdings, Inc. (Amex: PRZ), a provider of pain-focused medical and surgical solutions and services, today announced that it will voluntarily withdraw its common stock from listing on the American Stock Exchange ("AMEX"). PainCare's Board of Directors considered several factors that include the following:

  • Miami Rolls Out the Red Carpet for Latin Star Studded FedEx/St. Jude Gala

    St. Jude Children's Research Hospital(R), the world's premier pediatric cancer research and treatment center, celebrates its sixth annual FedEx/St. Jude Angels & Stars Gala on Saturday, May 17, at the Adrienne Arsht Center for the Performing Arts of Miami-Dade County.

  • INETICO, Inc. Creates Data Interface with TPABenefits, Inc. Offering a Powerful Care and Claims Management Solution

    INETICO, Inc. and TPABenefits, Inc. of San Antonio, TX announced today they have developed a data interface between the INETICO system and the TPABenefits Web Portal. This provides TPABenefits clients with a Care and Claims Management, Pre-Certification, and Wellness data source and allows Payors, TPA's, Providers, and Members to view electronically transmitted Pre-Certifications and Case Notes on the TPABenefits Web Portal.

  • Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session

    Alpharma Inc. (NYSE: ALO), a global specialty pharmaceutical company, today announced results from clinical trials that showed ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) capsules demonstrated clinically relevant features addressing abuse liability alongside a promising safety and efficacy profile. The Phase I and II studies, presented at the 27th Annual Scientific Session of the American Pain Society, examined the effects of ALO-01 when crushed -- a common method of abuse -- among recreational drug users and when taken whole, as intended, by chronic pain patients.

  • Phyhealth Signs Agreement with Argus Dental to Provide Dental Services for Pilot HMO

    Physicians Healthcare Management Group, Inc. (Phyhealth) (Pink Sheets: PHYH), a developer of health maintenance organizations (HMOs) in partnership with physicians, today announced that Phyhealth Plan Corporation, a wholly-owned subsidiary of Phyhealth, has signed an agreement with Argus Dental of Tampa, Florida to provide dental services for its Pilot HMO scheduled to be launched in the latter half of 2008.

  • eDiets.com(R) to Report First Quarter 2008 Results on Tuesday, May 13, 2008

    eDiets.com, Inc. (Nasdaq: DIET), leveraging the power of the Internet to bring diet, fitness and healthy lifestyle solutions to everyone, today announced that it will report results for its first quarter ended March 31, 2008, after the U.S. equity markets close on Tuesday, May 13, 2008.

  • Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions

    Alpharma Inc. (NYSE: ALO), a leading global specialty pharmaceutical company, announced today that two studies to be presented this week at the American Pain Society annual meeting demonstrate the efficacy, tolerability and positive pharmacokinetic profile of Alpharma Pharmaceuticals' FLECTOR(R) Patch (diclofenac epolamine topical patch) 1.3%, the first and only prescription anti-inflammatory pain relief patch in the United States. FLECTOR(R) Patch has been available since January in the United States for the topical treatment of acute pain due to minor strains, sprains and contusions.

  • BEMA(TM) Fentanyl Phase III Data Demonstrating Efficacy and Tolerability to be Presented at American Pain Society Annual Meeting

    BioDelivery Sciences International, Inc. (Nasdaq: BDSI) and commercial partner Meda Pharmaceuticals will present today and tomorrow, data from Phase III clinical pivotal trials for BEMA(TM) Fentanyl, a potential treatment for breakthrough pain (BTP) in opioid tolerant patients with cancer. The presentations will be made at the 27th Annual Scientific Meeting of the American Pain Society (APS) in Tampa, Florida.

  • New Survey Finds Enhanced Pain Management for Blood Draw and IV Insertions in Children Would Benefit Patients, Families and Nursing Staff

    According to a new survey of nurses to be presented tomorrow at the 27th annual meeting of the American Pain Society (APS), increasing the use of non-pharmacologic interventions (such as distraction techniques, parental coaching, and comfort positions) and pharmacologic options that do not cause treatment delays or vasoconstriction would enhance patient and staff satisfaction.(1) The survey, sponsored by Anesiva, Inc. (Nasdaq: ANSV) also found that 91 percent of respondents agree that better pain management for IV insertions and blood draws (peripheral venous access procedures) in children improves their job performance and 81 percent agree that it improves their job satisfaction.(1)

  • Children, Teens at Greater Risk Than Adults of Exposure to Damaging UV Radiation

    Although both adults and children are subject to the effects of ultraviolet (UV) radiation, younger eyes are more susceptible to exposure to the sun's harmful rays. A leading eye care professional notes that glasses with a UV-blocking coating and sunglasses do not offer complete protection, and advise parents also to consider UV-blocking contact lenses for children who need vision correction to fill in some of the UV blocking gaps left by these more traditional means.

  • Data from Randomized Pilot Study, Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008

    Twelve-month follow-up data from both a randomized pilot study and the real-world registry use of OrbusNeich's Genous Bio-engineered R stent, the world's first pro-healing stent, will be presented next week in a symposium at EuroPCR 2008 in Barcelona, Spain.

  • New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain

    Patients treated with lacosamide demonstrated sustained pain relief from diabetic neuropathic pain (DNP), compared to placebo-treated patients, according to data presented at the 27th annual meeting of the American Pain Society (APS) in Tampa, Fla.

Miami Top Jobs

    Quick Job Search

    Enter Keyword(s): Enter City: Select a State: Select a Category: Advanced Job Search Search by Category

     Ad links